JP2014513519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513519A5 JP2014513519A5 JP2013542608A JP2013542608A JP2014513519A5 JP 2014513519 A5 JP2014513519 A5 JP 2014513519A5 JP 2013542608 A JP2013542608 A JP 2013542608A JP 2013542608 A JP2013542608 A JP 2013542608A JP 2014513519 A5 JP2014513519 A5 JP 2014513519A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ccr4
- disease
- cancer
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 2
- 102000003826 Chemokine CCL17 Human genes 0.000 claims 2
- 108010082169 Chemokine CCL17 Proteins 0.000 claims 2
- 102000006433 Chemokine CCL22 Human genes 0.000 claims 2
- 108010083701 Chemokine CCL22 Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004498 CCR4 Receptors Human genes 0.000 claims 1
- 108010017317 CCR4 Receptors Proteins 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 241000244206 Nematoda Species 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 235000021310 complex sugar Nutrition 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42037010P | 2010-12-07 | 2010-12-07 | |
| US61/420,370 | 2010-12-07 | ||
| GB1020738.9 | 2010-12-07 | ||
| GB201020738A GB201020738D0 (en) | 2010-12-07 | 2010-12-07 | Antibodies |
| PCT/GB2011/052421 WO2012076883A1 (en) | 2010-12-07 | 2011-12-07 | Anti ccr4 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513519A JP2014513519A (ja) | 2014-06-05 |
| JP2014513519A5 true JP2014513519A5 (https=) | 2015-01-29 |
| JP6215707B2 JP6215707B2 (ja) | 2017-10-18 |
Family
ID=43531609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542608A Expired - Fee Related JP6215707B2 (ja) | 2010-12-07 | 2011-12-07 | 抗ｃｃｒ４抗体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8895007B2 (https=) |
| EP (1) | EP2649097A1 (https=) |
| JP (1) | JP6215707B2 (https=) |
| KR (1) | KR20130132903A (https=) |
| CN (1) | CN103328513B (https=) |
| AU (1) | AU2011340264B2 (https=) |
| BR (1) | BR112013014235A2 (https=) |
| CA (1) | CA2818313A1 (https=) |
| CO (1) | CO6761356A2 (https=) |
| EA (1) | EA201390813A1 (https=) |
| GB (1) | GB201020738D0 (https=) |
| IL (1) | IL226427A0 (https=) |
| MX (1) | MX2013006167A (https=) |
| NZ (1) | NZ612175A (https=) |
| SG (1) | SG190299A1 (https=) |
| WO (1) | WO2012076883A1 (https=) |
| ZA (1) | ZA201304723B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2512857A (en) | 2013-04-09 | 2014-10-15 | Cancer Res Technology | Cancer biomarker |
| US20170121419A1 (en) * | 2014-06-12 | 2017-05-04 | The General Hospital Corporation | Anti-human Chemokine (C-C motif) Receptor 4 Immunotoxins |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| JP6795505B2 (ja) * | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| IL256665B2 (en) * | 2015-07-23 | 2023-10-01 | Boehringer Ingelheim Int | IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US11299740B2 (en) * | 2017-01-30 | 2022-04-12 | Ofer Nussbaum | Artificial chemical entity comprising a DNA oligonucleotide aptamer that selectively binds MUC1 antigen |
| JP6811480B2 (ja) * | 2017-02-28 | 2021-01-13 | 日本全薬工業株式会社 | イヌ皮膚ｔ細胞リンパ腫細胞株 |
| JP7177445B2 (ja) * | 2017-05-19 | 2022-11-24 | 真吾 前田 | Ｃｃｒ４阻害による制御性ｔ細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法 |
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| CN108250290B (zh) * | 2018-02-23 | 2024-03-12 | 上海捌加壹医药科技有限公司 | Ccr4的n端重组蛋白及其用途 |
| CN114051532A (zh) * | 2019-05-24 | 2022-02-15 | 希望之城公司 | 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞 |
| CN111135310B (zh) * | 2019-12-24 | 2021-05-07 | 江苏省人民医院（南京医科大学第一附属医院） | 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用 |
| JP6960642B2 (ja) * | 2020-04-16 | 2021-11-05 | 国立研究開発法人国立国際医療研究センター | 呼吸器感染症の重症化の予測を補助する方法、バイオマーカーの測定値をモニタリングする方法、これらの方法に用いられる試薬キット、呼吸器感染症の重症化の予測を補助する装置およびコンピュータプログラム |
| CN111704668B (zh) * | 2020-06-27 | 2021-03-30 | 天津金域医学检验实验室有限公司 | 抗ccr4抗体及其在治疗癌症中的应用 |
| KR102900282B1 (ko) * | 2022-04-08 | 2025-12-22 | 국민대학교 산학협력단 | 케모카인 수용체 cxcr4에 대한 고 친화성 항체 |
| CN117187180B (zh) * | 2023-11-03 | 2024-01-26 | 四川大学 | 一种Th17细胞及其培养方法和应用及其诱导液 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| AU2004201168A1 (en) | 1999-01-15 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US6245332B1 (en) * | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| EP1050307A1 (en) | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 antagonists in sepsis |
| CN100455599C (zh) | 2000-03-03 | 2009-01-28 | 协和发酵工业株式会社 | 基因重组抗体及其抗体片段 |
| CA2439279A1 (en) | 2001-02-28 | 2002-09-06 | Protein Design Labs, Inc. | Chemokine receptors and disease |
| PT1449850E (pt) | 2001-08-31 | 2011-02-02 | Kyowa Hakko Kirin Co Ltd | Anticorpos humanos enxertados em rdc¿s e fragmentos desses anticorpos |
| AU2004279739A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Composition of antibody capable of specifically binding CCR4 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| US8802442B2 (en) | 2011-11-30 | 2014-08-12 | Eric B. Wheeldon | Apparatus and method for the remote sensing of blood in human feces and urine |
-
2010
- 2010-12-07 GB GB201020738A patent/GB201020738D0/en not_active Ceased
-
2011
- 2011-12-07 US US13/313,541 patent/US8895007B2/en not_active Expired - Fee Related
- 2011-12-07 EA EA201390813A patent/EA201390813A1/ru unknown
- 2011-12-07 BR BR112013014235A patent/BR112013014235A2/pt not_active IP Right Cessation
- 2011-12-07 KR KR20137017710A patent/KR20130132903A/ko not_active Withdrawn
- 2011-12-07 CA CA2818313A patent/CA2818313A1/en not_active Abandoned
- 2011-12-07 CN CN201180066005.9A patent/CN103328513B/zh not_active Expired - Fee Related
- 2011-12-07 EP EP11794570.9A patent/EP2649097A1/en not_active Withdrawn
- 2011-12-07 WO PCT/GB2011/052421 patent/WO2012076883A1/en not_active Ceased
- 2011-12-07 NZ NZ612175A patent/NZ612175A/en not_active IP Right Cessation
- 2011-12-07 MX MX2013006167A patent/MX2013006167A/es not_active Application Discontinuation
- 2011-12-07 AU AU2011340264A patent/AU2011340264B2/en not_active Ceased
- 2011-12-07 SG SG2013037577A patent/SG190299A1/en unknown
- 2011-12-07 JP JP2013542608A patent/JP6215707B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-19 IL IL226427A patent/IL226427A0/en unknown
- 2013-06-25 CO CO13150835A patent/CO6761356A2/es unknown
- 2013-06-25 ZA ZA2013/04723A patent/ZA201304723B/en unknown
-
2014
- 2014-10-16 US US14/515,892 patent/US9458238B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513519A5 (https=) | ||
| JP2012529280A5 (https=) | ||
| CN107646039B (zh) | 具有有效抗hiv活性的双特异性cxcr4-cd4多肽 | |
| ES2699591T3 (es) | Anticuerpos contra ST-2 humana soluble y ensayos | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2013519367A5 (https=) | ||
| JP2012012402A5 (https=) | ||
| CN117024588A (zh) | 抗cd19抗体在制备白血病治疗药物中的用途 | |
| JP2017522043A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| RU2008152443A (ru) | Антитела высокой аффинности к il-6-рецептору человека | |
| JP2019505527A5 (https=) | ||
| KR20240032930A (ko) | 사이토카인 방출 증후군을 예측하기 위한 다변량 모델 | |
| US12071479B2 (en) | Antibodies against ILT2 and use thereof | |
| RU2016136639A (ru) | Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины | |
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| JP2017507131A5 (https=) | ||
| JP2016507521A5 (https=) | ||
| WO2017140831A1 (en) | Antibodies for il-17c | |
| JP2022502024A5 (https=) | ||
| CN118324915A (zh) | 一种抗nkg2d纳米抗体及其制备方法与应用 | |
| JP2016534022A5 (https=) | ||
| US20220025034A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| JPWO2021053199A5 (https=) | ||
| CN118562002A (zh) | 一种抗人Siglec-9微纳抗体及其应用 |